Insider Buying at Karyopharm Signals Long‑Term Confidence and Possible Rally

Insider Buying Spurs Question Marks for Karyopharm

On January 31 , 2026, Cheng Sohanya Roshan, EVP and Chief Commercial Officer, executed a purchase of 32 415 restricted stock units (RSUs) that will vest in 2027 and 2028. The transaction was filed when the share price was $6.55—a modest 0.04 % uptick from the prior close—yet it generated an unusually high buzz of 208 % on social media. While the price itself is not a clear signal of confidence, the timing and volume of chatter suggest that insiders may be positioning themselves for a near‑term rally amid the company’s ongoing clinical pipeline development.

What the Buy May Mean for Investors

Roshan’s latest purchase is the first insider transaction in a year‑long streak of mostly modest buys and sells that have kept her stake near 111 000 shares. Historically, she has alternated between buying and selling around key corporate milestones: a bulk purchase in October 2025 coinciding with a major clinical study, a brief sale in mid‑September 2025 as the company reported a quarterly loss, and a larger buy in October 2025 that pushed her holdings to 79 000 shares. The current RSU award, which will convert to common stock over two years, indicates a longer‑term confidence in Karyopharm’s prospects, potentially aligning her interests with shareholders over the medium term.

For investors, the buy could be interpreted in two ways. First, it may signal that senior management believes the stock is undervalued relative to the company’s pipeline, particularly as Karyopharm continues to advance its dexamethasone‑combination therapy for multiple myeloma. Second, the sizeable media buzz—despite a neutral sentiment score of 0—could be a reaction to broader market volatility, given the stock’s recent 35 % yearly decline and negative price‑earnings ratio. In either case, the transaction adds another layer of complexity to an already volatile equity that has traded between $3.51 and $10.38 over the past year.

Cheng Sohanya Roshan: A Profile of Insider Activity

Roshan, who joined Karyopharm in 2015, has been a consistent, albeit cautious, participant in the company’s insider trading landscape. Her transaction history shows a pattern of opportunistic buying during periods of positive news and small‑scale selling when earnings miss expectations. The RSU award in 2026 marks a departure from her usual pattern, suggesting a shift toward longer‑term equity compensation that will vest over two years. This move could be a strategic response to the company’s evolving clinical calendar and a way to reinforce her commitment to shareholder value as Karyopharm seeks to navigate regulatory hurdles and market competition.

Her buying behavior aligns with other top executives: EVP‑CFO Lori Macomber and EVP‑CLO Michael Mano both executed sizable RSU purchases on the same day, reinforcing a sense of institutional confidence. Collectively, these moves indicate that the senior leadership team is aligning its personal financial interests with the company’s long‑term trajectory, which may be reassuring to investors concerned about management’s incentive structure.

Implications for Karyopharm’s Future

Karyopharm’s recent insider buying activity, especially the sizable RSU awards, may presage a strategic push toward commercialization of its lead programs. If the company can deliver clinical milestones in the next 12–18 months, the stock could experience a meaningful rebound. However, the negative price‑earnings ratio and steep annual decline underscore the risk that the market remains skeptical of the company’s revenue prospects. Investors should monitor upcoming trial results, regulatory filings, and any changes in insider holdings to gauge whether this buying trend translates into tangible shareholder value.